2,480 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Crowley Wealth Management Inc.

Crowley Wealth Management Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,480 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

Several other large investors also recently bought and sold shares of the company. Swedbank AB raised its stake in Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after acquiring an additional 189,622 shares during the period. Quest Partners LLC raised its holdings in shares of Gilead Sciences by 163.4% in the 3rd quarter. Quest Partners LLC now owns 8,400 shares of the biopharmaceutical company’s stock worth $704,000 after purchasing an additional 5,211 shares in the last quarter. Citizens Financial Group Inc. RI lifted its position in shares of Gilead Sciences by 5.6% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 6,321 shares of the biopharmaceutical company’s stock valued at $530,000 after acquiring an additional 337 shares during the last quarter. LPL Financial LLC raised its holdings in Gilead Sciences by 7.4% during the 3rd quarter. LPL Financial LLC now owns 1,137,381 shares of the biopharmaceutical company’s stock worth $95,358,000 after buying an additional 78,839 shares during the period. Finally, Concorde Asset Management LLC acquired a new position in Gilead Sciences in the 3rd quarter worth approximately $211,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $107.08 on Friday. The firm has a market cap of $133.35 billion, a P/E ratio of 289.41, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a 50-day moving average of $103.68 and a 200-day moving average of $93.85. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.95%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Royal Bank of Canada increased their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.29% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.